{
    "clinical_study": {
        "@rank": "129422", 
        "arm_group": {
            "arm_group_label": "Coenzyme Q10", 
            "arm_group_type": "Experimental", 
            "description": "400mg/day, 800mg/day, 1200/day and 2400mg/day"
        }, 
        "brief_summary": {
            "textblock": "The investigators hypothesise that measuring biomarkers of oxidative damage could better\n      inform investigators on the potential merits (and pitfalls) of CoQ10 supplementation in PD\n      subjects."
        }, 
        "brief_title": "Effects of High-dose Coenzyme Q10 on Biomarkers of Oxidative Damage and Clinical Outcome in Parkinson Disease", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Parkinson Disease", 
        "condition_browse": {
            "mesh_term": "Parkinson Disease"
        }, 
        "detailed_description": {
            "textblock": "Subjects with idiopathic PD will be recruited to a 10-week dose escalation study. Each\n      dosage (400mg/day, 800mg/day, 1200/day and 2400mg/day) will be consumed daily for two weeks.\n      Information on safety and fasting blood/urine samples will be collected. Primary endpoint is\n      plasma F2-isoprostanes (adjusted for arachidonate) while secondary endpoint is the change in\n      the total Unified Parkinson Disease Rating Scale (UPDRS) before and after treatment. Serum\n      phospholipase A2 activities, plasma all trans-retinol, plasma total tocopherol (sum of \u03b1-,\n      \u03b4- and \u03b3-tocopherol) and serum uric acid will be measured."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  idiopathic Parkinson disease\n\n          -  age >21 years\n\n          -  able to provide written informed consent\n\n        Exclusion Criteria:\n\n          -  diabetes mellitus, stroke, cardiac and renal diseases and cigarette smoking\n\n          -  major psychiatric disorder or drug and/or alcohol abuse/dependence\n\n          -  regular use of antioxidants, dietary supplements, traditional Chinese remedies,\n             non-steroidal anti-inflammatory drugs or immunosuppressive drugs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Months"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01892176", 
            "org_study_id": "DSRB/2010/00223"
        }, 
        "intervention": {
            "arm_group_label": "Coenzyme Q10", 
            "description": "400mg/day, 800mg/day, 1200/day and 2400mg/day", 
            "intervention_name": "coenzyme q10", 
            "intervention_type": "Dietary Supplement"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Coenzyme Q10", 
                "Ubiquinone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "coenzyme Q10, Parkinson disease, oxidative damage", 
        "lastchanged_date": "July 8, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Singapore", 
                    "country": "Singapore", 
                    "zip": "119228"
                }, 
                "name": "National University Health System"
            }
        }, 
        "location_countries": {
            "country": "Singapore"
        }, 
        "number_of_arms": "1", 
        "official_title": "Effects of High-dose Coenzyme Q10 on Biomarkers of Oxidative Damage and Clinical Outcome in Parkinson Disease", 
        "overall_official": {
            "affiliation": "National University Health System", 
            "last_name": "Raymond Seet, MBBS", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Singapore: Health Sciences Authority", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Biomarkers of oxidative damage", 
            "safety_issue": "No", 
            "time_frame": "10 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01892176"
        }, 
        "responsible_party": {
            "investigator_affiliation": "National University Hospital, Singapore", 
            "investigator_full_name": "Medicine", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Total Unified Parkinson's Disease Rating Scale (UPDRS)", 
            "safety_issue": "No", 
            "time_frame": "10 weeks"
        }, 
        "source": "National University Hospital, Singapore", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National University Hospital, Singapore", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}